Canada - English - Health Canada

les laboratoires vachon inc. - ascorbic acid (ascorbic acid); vitamin e (dl-alpha tocopheryl acetate); folic acid; vitamin b1 (thiamine mononitrate); vitamin b2; nicotinamide; vitamin b6 (pyridoxine hydrochloride); vitamin b12; biotin; d-pantothenic acid (calcium d-pantothenate); copper (cupric oxide); zinc (zinc sulfate) - tablet - 600mg; 30unit; .4mg; 22mg; 10mg; 100mg; 6mg; 12mcg; 45mcg; 25mg; 3mg; 23.9mg - ascorbic acid (ascorbic acid) 600mg; vitamin e (dl-alpha tocopheryl acetate) 30unit; folic acid .4mg; vitamin b1 (thiamine mononitrate) 22mg; vitamin b2 10mg; nicotinamide 100mg; vitamin b6 (pyridoxine hydrochloride) 6mg; vitamin b12 12mcg; biotin 45mcg; d-pantothenic acid (calcium d-pantothenate) 25mg; copper (cupric oxide) 3mg; zinc (zinc sulfate) 23.9mg - vitamins & minerals

Canada - English - Health Canada

les laboratoires suisse inc. - zinc (zinc gluconate); vitamin e (vitamin e); vitamin b6 (pyridoxine hydrochloride); copper (cupric sulfate); selenium (yeast) - tablet - 20mg; 20unit; 10mg; 2.5mg; 15mcg - zinc (zinc gluconate) 20mg; vitamin e (vitamin e) 20unit; vitamin b6 (pyridoxine hydrochloride) 10mg; copper (cupric sulfate) 2.5mg; selenium (yeast) 15mcg

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - cholesterol (unii: 97c5t2uq7j) (cholesterol - unii:97c5t2uq7j) - cholesterol 6 [hp_x] in 1 ml - for temporary relief of symptoms related to adrenal glands such as fatigue and low energy.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to adrenal glands such as fatigue and low energy.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 10.82 mg perindopril arginine 5 mg - lipid modifying agents

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 21.64 mg perindopril arginine 5 mg - lipid modifying agents

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 43.28 mg perindopril arginine 5 mg - lipid modifying agents

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 10.82 mg perindopril arginine 10 mg - lipid modifying agents

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 21.64 mg perindopril arginine 10 mg - lipid modifying agents

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - atorvastatin calcium, trihydrate, perindopril arginine - hard capsule - atorvastatin calcium trihydrate 43.28 mg perindopril arginine 10 mg - lipid modifying agents

United States - English - NLM (National Library of Medicine)

ironwood pharmaceuticals, inc. - lesinurad (unii: 09erp08i3w) (lesinurad - unii:09erp08i3w), allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - lesinurad 200 mg - duzallo®, a combination of lesinurad, a uric acid transporter 1 (urat1) inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone [see clinical studies (14) ]. duzallo is not recommended for the treatment of asymptomatic hyperuricemia. the use of duzallo is contraindicated in the following conditions: - severe renal impairment (eclcr less than 30 ml/min), end-stage renal disease, kidney transplant recipients, or patients on dialysis [see use in specific populations (8.6) ]. - tumor lysis syndrome or lesch-nyhan syndrome [see use in specific populations (8.8) ]. - known hypersensitivity to allopurinol, including previous occurrence of skin rash [see warnings and precautions (5.2) ]. risk summary there are no available human data on use of duzallo or lesinurad in pregnant women to inform a drug-associated risk of adverse